A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 332 participants.

Also called NCT01447147

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 332 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01447147
Other papers using this trial's data
  • The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial The lancet. Diabetes & endocrinology, 2015-09 DOI, PubMed 26268910

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Czechia, Germany, Hungary, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01447147. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo
Intervention (Drug)
CCX140-B
Intervention (Drug)
CCX140-B
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01447147
Content hash
7ac39e8ef6783378c4c69276cd10d106aeb99b67f3c25f7665d4b952b6c22d8b